- Home
- LYEL vs NYXH Comparison
LYEL vs NYXH Comparison
Compare LYEL & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- NYXH
- Stock Information
- Founded
- LYEL 2018
- NYXH 2009
- Country
- LYEL United States
- NYXH Belgium
- Employees
- LYEL N/A
- NYXH N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- NYXH Medical/Dental Instruments
- Sector
- LYEL Health Care
- NYXH Health Care
- Exchange
- LYEL Nasdaq
- NYXH Nasdaq
- Market Cap
- LYEL 263.9M
- NYXH 261.1M
- IPO Year
- LYEL 2021
- NYXH 2021
- Fundamental
- Price
- LYEL $0.62
- NYXH $8.01
- Analyst Decision
- LYEL Sell
- NYXH Strong Buy
- Analyst Count
- LYEL 2
- NYXH 5
- Target Price
- LYEL $1.00
- NYXH $17.00
- AVG Volume (30 Days)
- LYEL 1.5M
- NYXH 44.5K
- Earning Date
- LYEL 11-07-2024
- NYXH 11-06-2024
- Dividend Yield
- LYEL N/A
- NYXH N/A
- EPS Growth
- LYEL N/A
- NYXH N/A
- EPS
- LYEL N/A
- NYXH N/A
- Revenue
- LYEL $63,000.00
- NYXH $5,668,079.00
- Revenue This Year
- LYEL N/A
- NYXH $37.10
- Revenue Next Year
- LYEL N/A
- NYXH $418.12
- P/E Ratio
- LYEL N/A
- NYXH N/A
- Revenue Growth
- LYEL N/A
- NYXH 32.65
- 52 Week Low
- LYEL $0.58
- NYXH $4.00
- 52 Week High
- LYEL $3.26
- NYXH $20.00
- Technical
- Relative Strength Index (RSI)
- LYEL 27.76
- NYXH 43.45
- Support Level
- LYEL $0.58
- NYXH $7.74
- Resistance Level
- LYEL $0.95
- NYXH $8.45
- Average True Range (ATR)
- LYEL 0.07
- NYXH 0.47
- MACD
- LYEL -0.02
- NYXH 0.06
- Stochastic Oscillator
- LYEL 6.48
- NYXH 45.81
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.